Logo image of TDOC

TELADOC HEALTH INC (TDOC) Stock Fundamental Analysis

USA - NYSE:TDOC - US87918A1051 - Common Stock

8.53 USD
-0.49 (-5.43%)
Last: 10/17/2025, 8:04:00 PM
8.54 USD
+0.01 (+0.12%)
After Hours: 10/17/2025, 8:04:00 PM
Fundamental Rating

3

Taking everything into account, TDOC scores 3 out of 10 in our fundamental rating. TDOC was compared to 35 industry peers in the Health Care Technology industry. TDOC has a bad profitability rating. Also its financial health evaluation is rather negative. TDOC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

TDOC had negative earnings in the past year.
TDOC had a positive operating cash flow in the past year.
In the past 5 years TDOC always reported negative net income.
Of the past 5 years TDOC 4 years had a positive operating cash flow.
TDOC Yearly Net Income VS EBIT VS OCF VS FCFTDOC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5B -10B

1.2 Ratios

Looking at the Return On Assets, with a value of -7.17%, TDOC is in the better half of the industry, outperforming 65.71% of the companies in the same industry.
TDOC has a better Return On Equity (-14.58%) than 62.86% of its industry peers.
Industry RankSector Rank
ROA -7.17%
ROE -14.58%
ROIC N/A
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
TDOC Yearly ROA, ROE, ROICTDOC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

Looking at the Gross Margin, with a value of 70.26%, TDOC is in the better half of the industry, outperforming 74.29% of the companies in the same industry.
In the last couple of years the Gross Margin of TDOC has remained more or less at the same level.
TDOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
TDOC Yearly Profit, Operating, Gross MarginsTDOC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

3

2. Health

2.1 Basic Checks

TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TDOC has been increased compared to 1 year ago.
The number of shares outstanding for TDOC has been increased compared to 5 years ago.
Compared to 1 year ago, TDOC has a worse debt to assets ratio.
TDOC Yearly Shares OutstandingTDOC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TDOC Yearly Total Debt VS Total AssetsTDOC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

Based on the Altman-Z score of -6.31, we must say that TDOC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.31, TDOC is doing worse than 88.57% of the companies in the same industry.
TDOC has a debt to FCF ratio of 6.57. This is a slightly negative value and a sign of low solvency as TDOC would need 6.57 years to pay back of all of its debts.
TDOC has a Debt to FCF ratio of 6.57. This is comparable to the rest of the industry: TDOC outperforms 54.29% of its industry peers.
A Debt/Equity ratio of 0.70 indicates that TDOC is somewhat dependend on debt financing.
TDOC has a Debt to Equity ratio of 0.70. This is in the lower half of the industry: TDOC underperforms 71.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF 6.57
Altman-Z -6.31
ROIC/WACCN/A
WACC8.14%
TDOC Yearly LT Debt VS Equity VS FCFTDOC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

TDOC has a Current Ratio of 2.67. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.67, TDOC perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
A Quick Ratio of 2.58 indicates that TDOC has no problem at all paying its short term obligations.
TDOC has a Quick ratio of 2.58. This is comparable to the rest of the industry: TDOC outperforms 54.29% of its industry peers.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2.58
TDOC Yearly Current Assets VS Current LiabilitesTDOC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

3

3. Growth

3.1 Past

TDOC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.75%.
The Revenue has decreased by -2.57% in the past year.
Measured over the past years, TDOC shows a very strong growth in Revenue. The Revenue has been growing by 35.95% on average per year.
EPS 1Y (TTM)7.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.14%
Revenue 1Y (TTM)-2.57%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-1.64%

3.2 Future

The Earnings Per Share is expected to grow by 6.70% on average over the next years.
TDOC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.58% yearly.
EPS Next Y7.84%
EPS Next 2Y16.54%
EPS Next 3Y11.86%
EPS Next 5Y6.7%
Revenue Next Year-1.83%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.37%
Revenue Next 5Y2.58%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TDOC Yearly Revenue VS EstimatesTDOC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
TDOC Yearly EPS VS EstimatesTDOC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -10 -20 -30 -40 -50

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TDOC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TDOC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TDOC Price Earnings VS Forward Price EarningsTDOC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TDOC indicates a rather cheap valuation: TDOC is cheaper than 85.71% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TDOC indicates a rather cheap valuation: TDOC is cheaper than 94.29% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.96
EV/EBITDA 10.81
TDOC Per share dataTDOC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.54%
EPS Next 3Y11.86%

More info and screens

0

5. Dividend

5.1 Amount

TDOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TELADOC HEALTH INC

NYSE:TDOC (10/17/2025, 8:04:00 PM)

After market: 8.54 +0.01 (+0.12%)

8.53

-0.49 (-5.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)07-29 2025-07-29/amc
Earnings (Next)10-22 2025-10-22/amc
Inst Owners75.05%
Inst Owner Change0.17%
Ins Owners0.62%
Ins Owner Change6.12%
Market Cap1.51B
Analysts68.13
Price Target9.21 (7.97%)
Short Float %13.63%
Short Ratio3.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.76%
Min EPS beat(2)-54.19%
Max EPS beat(2)28.67%
EPS beat(4)2
Avg EPS beat(4)-1.86%
Min EPS beat(4)-54.19%
Max EPS beat(4)32.44%
EPS beat(8)5
Avg EPS beat(8)4.86%
EPS beat(12)8
Avg EPS beat(12)-761.2%
EPS beat(16)11
Avg EPS beat(16)-739.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.43%
Min Revenue beat(2)-0.51%
Max Revenue beat(2)-0.35%
Revenue beat(4)0
Avg Revenue beat(4)-0.8%
Min Revenue beat(4)-1.82%
Max Revenue beat(4)-0.35%
Revenue beat(8)0
Avg Revenue beat(8)-1.61%
Revenue beat(12)0
Avg Revenue beat(12)-1.47%
Revenue beat(16)0
Avg Revenue beat(16)-1.39%
PT rev (1m)0%
PT rev (3m)1.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-39.5%
EPS NY rev (1m)-0.45%
EPS NY rev (3m)0.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.59
P/FCF 9.96
P/OCF 4.97
P/B 1.06
P/tB N/A
EV/EBITDA 10.81
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)0.86
FCFY10.04%
OCF(TTM)1.72
OCFY20.13%
SpS14.39
BVpS8.05
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.17%
ROE -14.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.26%
FCFM 5.95%
ROA(3y)-115.95%
ROA(5y)-70.6%
ROE(3y)-222.82%
ROE(5y)-134.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.2%
F-Score5
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0.7
Debt/FCF 6.57
Debt/EBITDA 5.63
Cap/Depr 42.28%
Cap/Sales 5.99%
Interest Coverage N/A
Cash Conversion 171.95%
Profit Quality N/A
Current Ratio 2.67
Quick Ratio 2.58
Altman-Z -6.31
F-Score5
WACC8.14%
ROIC/WACCN/A
Cap/Depr(3y)48.66%
Cap/Depr(5y)42.76%
Cap/Sales(3y)6.01%
Cap/Sales(5y)4.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.14%
EPS Next Y7.84%
EPS Next 2Y16.54%
EPS Next 3Y11.86%
EPS Next 5Y6.7%
Revenue 1Y (TTM)-2.57%
Revenue growth 3Y8.13%
Revenue growth 5Y35.95%
Sales Q2Q%-1.64%
Revenue Next Year-1.83%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.37%
Revenue Next 5Y2.58%
EBIT growth 1Y14.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year141.27%
EBIT Next 3Y35.38%
EBIT Next 5Y20.65%
FCF growth 1Y137.81%
FCF growth 3Y9.25%
FCF growth 5Y54.93%
OCF growth 1Y24.92%
OCF growth 3Y14.82%
OCF growth 5Y57.92%